Polycythemia vera

In this study, we conducted experiments to determine mRNA expression of above genes in PV patients by realtime-PCR and CA125 concentration by ELISA. Results showed that expression of klotho, LAG3, CTLA-4 and PD-1 genes was decreased in PV patients, indicating that the immune tolerance was inactivated in PV patients.

10p tamynhan10 24-10-2020 13 1   Download

Bài giảng Những rối loạn tăng sinh tủy (Myeloproliferative neoplasms) trình bày những nội dung chính như: Bạch cầu mạn dòng tủy (chronic myelogenous leukemia: CML), đa hồng cầu nguyên phát (Polycythemia vera: PV), tăng tiểu cầu nguyên phát (Essential thrombocythemia: ET), tăng tiểu cầu nguyên phát (Essential thrombocythemia: ET). Mời các bạn cùng tham khảo.

57p tangtuy04 23-03-2016 101 10   Download

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a

17p dauphong3 03-01-2012 67 4   Download

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: T Polycythemia vera as a presentation of renal angiomyolipoma: a case report

3p thulanh30 20-12-2011 47 2   Download

Etiology Megakaryocytopoiesis and platelet production depend upon thrombopoietin and its receptor, Mpl. As in the case of early erythroid and myeloid progenitor cells, early megakaryocytic progenitors require the presence of interleukin 3 (IL-3) and stem cell factor for optimal proliferation in addition to thrombopoietin. Their subsequent development is also enhanced by the chemokine stromal cell–derived factor 1 (SDF-1). However, megakaryocyte maturation and differentiation require thrombopoietin.

5p thanhongan 07-12-2010 89 4   Download

Complications Perhaps no other condition in clinical medicine has caused otherwise astute physicians to intervene inappropriately more often than thrombocytosis, particularly if the platelet count is 1 x 106/µL. It is commonly believed that a high platelet count causes intravascular stasis and thrombosis; however, no controlled clinical study has ever established this association, and in patients younger than age 60, the incidence of thrombosis was not greater in patients with thrombocytosis than in age-matched controls.

8p thanhongan 07-12-2010 65 3   Download

Table 103-4 Risk Stratification for Idiopathic Myelofibrosis A. Prognostic factorsa Hemoglobin 30,000/µL Number of prognostic factors Risk group Median survival (months) 0 Low 93 1–2 High 17 B. Prognostic factorsb Hemoglobin 1% Number of prognostic factors Risk group Median survival (months) 0–1 Low 99 2–3 High 21 C.

5p thanhongan 07-12-2010 83 3   Download

Chronic Idiopathic Myelofibrosis: Treatment No specific therapy exists for chronic IMF. Anemia may be due to gastrointestinal blood loss and exacerbated by folic acid deficiency, and in rare instances, pyridoxine therapy has been effective. However, anemia is more often due to ineffective erythropoiesis uncompensated by extramedullary hematopoiesis in the spleen and liver. Neither recombinant erythropoietin nor androgens, such as Danazol, have proved consistently effective as therapy for anemia.

5p thanhongan 07-12-2010 72 3   Download

Diagnosis When PV presents with erythrocytosis in combination with leukocytosis, thrombocytosis, or both, the diagnosis is apparent. However, when patients present with an elevated hemoglobin or hematocrit alone, or with thrombocytosis alone, the diagnostic evaluation is more complex because of the many diagnostic possibilities (Table 103-2). Furthermore, unless the hemoglobin level is ≥20 gm% (hematocrit ≥60%), it is not possible to distinguish PV from disorders causing plasma volume contraction.

5p thanhongan 07-12-2010 86 5   Download

The etiology of PV is unknown. Although nonrandom chromosome abnormalities such as 20q, trisomy 8, and especially 9p, have been documented in up to 30% of untreated PV patients, unlike CML no consistent cytogenetic abnormality has been associated with the disorder. However, a mutation in the autoinhibitory, pseudokinase domain of the tyrosine kinase JAK2—which replaces valine with phenylalanine (V617F), causing constitutive activation of the kinase— appears to have a central role in the pathogenesis of PV.

5p thanhongan 07-12-2010 71 4   Download

Complications The major clinical complications of PV relate directly to the increase in blood viscosity associated with red cell mass elevation and indirectly to the increased turnover of red cells, leukocytes, and platelets with the attendant increase in uric acid and cytokine production. The latter appears to be responsible for the increase in peptic ulcer disease and for the pruritus associated with this disorder, although formal proof for this has not been obtained. A sudden massive increase in spleen size can be associated with splenic infarction or progressive cachexia.

5p thanhongan 07-12-2010 70 4   Download

Chronic Idiopathic Myelofibrosis Chronic IMF (other designations include agnogenic myeloid metaplasia or myelofibrosis with myeloid metaplasia) is a clonal disorder of a multipotent hematopoietic progenitor cell of unknown etiology characterized by marrow fibrosis, extramedullary hematopoiesis, and splenomegaly. Chronic IMF is the least common chronic myeloproliferative disorder, and establishing this diagnosis in the absence of a specific clonal marker is difficult because myelofibrosis and splenomegaly are also features of both PV and CML.

5p thanhongan 07-12-2010 65 3   Download

This marrow section shows the marrow cavity replaced by fibrous tissue composed of reticulin fibers and collagen. When this fibrosis is due to a primary hematologic process, it is called myelofibrosis. When the fibrosis is secondary to a tumor or a granulomatous process, it is called myelophthisis. Diagnosis While the clinical picture described above is characteristic of chronic IMF, all of the clinical features described can also be observed in PV or CML.

5p thanhongan 07-12-2010 66 3   Download

Harrison's Internal Medicine Chapter 103.

5p thanhongan 07-12-2010 94 5   Download

The differential diagnostic possibilities are much fewer when the spleen is "massively enlarged," palpable more than 8 cm below the left costal margin or its drained weight is ≥1000 g (Table 60-3). The vast majority of such patients will have non-Hodgkin's lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, chronic myelogenous leukemia, myelofibrosis with myeloid metaplasia, or polycythemia vera.

5p konheokonmummim 03-12-2010 79 4   Download

Approach to the Patient: Polycythemia As shown in Fig. 58-18, the first step is to document the presence of an increased red cell mass using the principle of isotope dilution by administering 51 Cr-labeled autologous red blood cells to the patient and sampling blood radioactivity over a 2-h period. If the red cell mass is normal (36 mL/kg in men, 32 mL/kg in women), serum EPO levels should be measured. If EPO levels are low or unmeasurable, the patient most likely has polycythemia vera.

5p konheokonmummim 03-12-2010 72 6   Download